Marshall Wace, LLP Mirati Therapeutics, Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$27.8 - $45.35 $12.2 Million - $19.8 Million	-437,179 Reduced 74.82%	147,144 $6.41 Million
Q2 2023 Aug 14, 2023	BUY	$36.13 - $49.49 $1.15 Million - $1.57 Million	31,709 Added 5.74%	584,323 $21.1 Million
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $20.2 Million - $30 Million	552,614 New	552,614 $20.5 Million
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $6.32 Million - $12.6 Million	-83,364 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $5.69 Million - $8.21 Million	43,132 Added 107.21%	83,364 $12.2 Million
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $590,621 - $793,201	-4,470 Reduced 10.0%	40,232 $7.12 Million
Q2 2021 Aug 13, 2021	SELL	$144.0 - $179.73 $409,248 - $510,792	-2,842 Reduced 5.98%	44,702 $7.22 Million
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $51.3 Million - $71.6 Million	-323,062 Reduced 87.17%	47,544 $8.14 Million
Q4 2020 Feb 16, 2021	SELL	$162.05 - $240.27 $9.37 Million - $13.9 Million	-57,793 Reduced 13.49%	370,606 $81.4 Million
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $48.5 Million - $71.7 Million	428,399 New	428,399 $71.1 Million
Q1 2020 May 15, 2020	SELL	$69.78 - $116.21 $522,093 - $869,483	-7,482 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $529,426 - $964,130	7,482 New	7,482 $964,000
Q2 2019 Aug 14, 2019	SELL	$59.49 - $104.71 $288,704 - $508,157	-4,853 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$43.65 - $78.95 $203,103 - $367,354	4,653 Added 2326.5%	4,853 $356,000
Q4 2018 Feb 14, 2019	BUY	$32.0 - $47.43 $6,400 - $9,486	200 New	200 $8,000
Q2 2018 Aug 14, 2018	SELL	$26.05 - $52.4 $227,677 - $457,976	-8,740 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$17.2 - $34.95 $150,328 - $305,463	8,740 New	8,740 $268,000

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account